Auxano Advisors LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 16.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,724 shares of the company’s stock after acquiring an additional 2,518 shares during the quarter. Johnson & Johnson comprises 1.1% of Auxano Advisors LLC’s investment portfolio, making the stock its 23rd largest position. Auxano Advisors LLC’s holdings in Johnson & Johnson were worth $2,747,000 as of its most recent SEC filing.
A number of other large investors have also recently modified their holdings of the business. LCM Capital Management Inc boosted its holdings in Johnson & Johnson by 0.7% in the fourth quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock worth $1,667,000 after acquiring an additional 61 shares in the last quarter. Arbor Investment Advisors LLC lifted its holdings in shares of Johnson & Johnson by 2.3% during the fourth quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock valued at $476,000 after purchasing an additional 61 shares in the last quarter. Sierra Capital LLC lifted its holdings in shares of Johnson & Johnson by 0.6% during the fourth quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock valued at $1,773,000 after purchasing an additional 61 shares in the last quarter. Retirement Planning Group lifted its holdings in shares of Johnson & Johnson by 1.8% during the fourth quarter. Retirement Planning Group now owns 3,437 shares of the company’s stock valued at $607,000 after purchasing an additional 62 shares in the last quarter. Finally, Lockerman Financial Group Inc. increased its position in Johnson & Johnson by 2.4% during the fourth quarter. Lockerman Financial Group Inc. now owns 2,684 shares of the company’s stock valued at $474,000 after acquiring an additional 62 shares during the last quarter. Institutional investors own 67.57% of the company’s stock.
Wall Street Analyst Weigh In
A number of analysts recently commented on the company. StockNews.com assumed coverage on Johnson & Johnson in a research report on Thursday, May 18th. They set a “strong-buy” rating for the company. Barclays upped their price target on Johnson & Johnson from $171.00 to $175.00 in a research report on Monday. Stifel Nicolaus upped their price target on Johnson & Johnson from $165.00 to $175.00 in a research report on Friday. JPMorgan Chase & Co. increased their target price on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research report on Friday. Finally, Atlantic Securities cut their target price on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research report on Wednesday, April 19th. Eight investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $171.60.
Johnson & Johnson Price Performance
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a return on equity of 37.01% and a net margin of 13.35%. The firm had revenue of $25.53 billion for the quarter, compared to the consensus estimate of $24.63 billion. During the same period in the prior year, the business posted $2.59 earnings per share. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. Equities analysts forecast that Johnson & Johnson will post 10.75 EPS for the current year.
Johnson & Johnson Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be issued a dividend of $1.19 per share. The ex-dividend date is Friday, August 25th. This represents a $4.76 annualized dividend and a yield of 2.78%. Johnson & Johnson’s payout ratio is currently 96.36%.
Insiders Place Their Bets
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.20% of the stock is currently owned by company insiders.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Stock Average Calculator
- 3 Housing Stocks to Avoid as Interest Rates Rise
- What Are Defense Contractor Stocks? How to Invest in Defense
- AMC: Is a Big Squeeze in the Coming Attractions?
- Video Game Stocks: How to Invest in Gaming
- Rivian: A Roaring Rise Or Time To Cash Out?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
